| OCR Text |
Show Diagnostic Algorithm for Patients With Suspected Giant Cell Arteritis Mays A. El-Dairi, MD, Lan Chang, MD, Alan D. Proia, MD, PhD, Thomas J. Cummings, MD, Sandra S. Stinnett, DrPH, M. Tariq Bhatti, MD Background: To identify clinical and laboratory factors contributing to the diagnosis of giant cell arteritis (GCA) and develop a diagnostic algorithm for the evaluation of GCA. Methods: Retrospective review of 213 consecutive cases of temporal artery biopsy (TAB) seen at a single academic center over a 10-year period (2000-2009). Pathologic specimens were re-reviewed and agreement between the original and second readings was assessed. A composite clinical suspicion score was created by adding 1 point for each of the following criteria: anterior extracranial circula-tion ischemia, new onset headache, abnormal laboratory results (erythrocyte sedimentation rate, C-reactive protein (CRP), or platelet count), jaw claudication, abnormal or tender superficial temporal artery, constitutional symptoms, and polymyalgia rheumatica; one point was subtracted if a comorbid condition could explain a criterion. Results: Of the 204 TABs analyzed, pathologic findings were confirmatory in 49 (24.0%) and suggestive in 12 (5.9%). TAB-positive patients were more likely to be older (age 75.2 ± 7.8 vs 69.7 ± 11.0 years, P = 0.0002), com-plain of jaw claudication (relative-risk = 3.26, P = 0.0014), and have thrombocytosis (relative-risk = 3.3, P = 0.0072) and elevated CRP (relative-risk = 1.8, P = 0.037). None of the patients with a clinical score less than 2 had a positive TAB. Diabetes mellitus and kidney disease were often the explanation for the symptoms and abnormal clinical finding(s) that led to a negative TAB. Conclusions: We propose a clinical algorithm that is highly predictive for a positive TAB and can be valuable in the evaluation process of suspected cases of GCA. Journal of Neuro-Ophthalmology 2015;35:246-253 doi: 10.1097/WNO.0000000000000234 © 2015 by North American Neuro-Ophthalmology Society Giant cell arteritis (GCA), also known as temporal or cranial arteritis, is the most common primary vasculitis of the elderly in the Western world (1). The prevalence among whites older than 50 years is 10-25/100,000 (1,2). Multisystem involvement is often the case, affecting the ocular and cerebral circulations. Because of the variabil-ity and sometimes paucity of disease manifestations, the clinical diagnosis can be challenging, yet critical, in prevent-ing the devastating complications of visual loss (3,4) and neurological deficits (3). GCA affects medium- to large-sized arteries, with a preferential effect on branches of the internal and external carotid arteries (5). Blindness and stroke are feared compli-cations because of inflammation-induced vascular occlusion (5). Headache, the most common symptom in patients with GCA, is believed to be due to inflammation of branches of the external carotid artery (6), and jaw claudication, which has been shown to be a specific symptom of GCA, is a con-sequence of ischemia to the masseter muscle supplied by the maxillary artery (7,8). In 1990, the American College of Rheumatology (ACR) published a 5-point scoring system for diagnosing GCA that was initially developed for research purposes. A score of 3 or more had a sensitivity of 93.5% and specificity of 91.2% in distinguishing GCA from other vasculitides (9,10). With these criteria, it is possible to make the diagnosis of GCA without a temporal artery biopsy (TAB) (11). However, most experts recommend a TAB when GCA is suspected because the results of a TAB significantly increase the agreement between the clinical diagnosis and the ACR criteria (12,13). Departments of Ophthalmology (MAE-D, LC, ADP, TJC, SSS, MTB), Pathology (ADP, TJC), Biostatistics and Bioinformatics (SSS), and Neurology (MTB), Duke Eye Center and Duke University Medical Center, Durham, North Carolina. Supported by unrestricted departmental research grant from Research to Prevent Blindness, Inc. M. A. El-Dairi is a consultant for Prana Pharmaceuticals. M. T. Bhatti is a consultant for Novartis pharmaceuticals. The remaining authors report no conflicts of interest. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the full text and PDF versions of this article on the journal's Web site (www. jneuro-ophthalmology.com). Address correspondence to M. Tariq Bhatti, MD, Departments of Ophthalmology and Neurology, Duke University Eye Center, 2351 Erwin Road, DUMC 3802, Durham, NC 27710-3802; E-mail: tariq. bhatti@duke.edu 246 El-Dairi et al: J Neuro-Ophthalmol 2015; 35: 246-253 Original Contribution Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. The goal of our study was to discern clinical and laboratory findings that may improve the diagnostic yield of a positive TAB. We compiled and reviewed our 10-year experience at Duke University Medical Center and per-formed a review of the clinical studies published in the English literature to derive an algorithm that would be useful in determining the risk for GCA before obtaining a TAB. METHODS The Institutional Review Board at Duke University Medical Center approved this retrospective study. The Department of Pathology electronic database (Cerner PathNet, North Kansas City, MO) was used to identify all patients who underwent a TAB at Duke University Medical Center from 2000 to 2009. Corresponding electronic and paper medical records were reviewed to gather clinical, demographic, pathologic, and laboratory information. Coexisting ocular and medical conditions were collected. Visual acuity measurements at presentation and at the last eye examina-tion were recorded and the surgical specialty obtaining the TAB, length of the TAB specimen, and number of days on corticosteroid before the time of the TAB. All TABs processed at Duke University Medical Center were cut into 6 to 10 cross sections, depending on the vessel length, and then the cross sections were prepared as ten slides containing 5 mm histological sections of every cross section. Each slide represented a "level" or "step section" with 50 mm between slides. Thus, 500 mm of each of the multiple artery cross sections was evaluated to minimize the possibility of a skip lesion being missed during histological evaluation. Seven slides were stained with hematoxylin and eosin, 1 slide with elastic stain to evaluate the internal elastic lamina, 1 slide with Masson trichrome stain to highlight scarring, and 1 slide with Congo red to evaluate for amyloid deposition. Three inflammatory markers were measured: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and platelet count. Three methods were used to identify the upper limits of normal for the ESR: 1. ESR . 50 as per ACR criteria 2. The formula of Miller et al (14): Male: age/2. Female: (age + 10)/2. 3. The formula of Hayreh et al (15): Male: 17.3+ (0.18 · age). Female: 22.1 + (0.18 · age). We defined an elevated CRP as .0.5 mg/dL and an elevated platelet count as .400,000/mL. The association between symptoms or laboratory findings and a positive/healed TAB was determined by using contingency tables and chi-square analyses. Statistical signif-icance was defined as P # 0.05. Equivocal biopsies were excluded from the pathological analysis. Risk factors meeting statistical significance and odds ratios were tabulated. With the aim of creating a numerical score that would improve the sensitivity of a TAB, 2 score models were created: 1. Composite score for clinical suspicion calculated by add-ing 1 point for each item on the following list: 1) new onset headache, 2) scalp tenderness or abnormal super-ficial temporal artery (STA) on examination, 3) elevation of any inflammatory markers (ESR, CRP, or platelet count), 4) evidence of new onset clinical ischemia involv-ing the anterior extracranial vasculature, 5) jaw claudica-tion, and 6) signs and symptoms consistent with polymyalgia rheumatica (PMR). One point was sub-tracted for each sign or symptom that could be explained by an alternative condition (e.g., poorly controlled dia-betes mellitus and evidence of ischemia, kidney disease, chronic rheumatologic condition, or central retinal artery occlusion in the setting of carotid artery occlusion). 2. A weighted score for clinical suspicion was created by the addition of each statistically significant variable tested multiplied by its own relative risk (RR). An area under the receiver operating curve (ROC) was created for each of the above scores, and the sensitivity and specificity were calculated. The TAB pathology report was reviewed, and slides from all cases were re-reviewed in a masked fashion by one of the authors (A.D.P.) (see Supplemental Digital Content, Figure E1, http://links.lww.com/WNO/A145). Positive TABs were labeled as active or healed arteritis. Active GCA was defined as inflammation comprising lymphocytes, epithelioid histiocytes, occasional giant cells, and disrup-tion/ loss of the internal elastic lamina (16,17). Healed arter-itis was identified and distinguished from age-related change by diffuse and marked intimal thickening, large areas of absent internal elastic lamina, asymmetric (eccentric) atro-phy and fibrosis of the tunica media, adventitial or trans-mural scarring, and sometimes vascularization of the media or residual foci of lymphocytes (17,18). The presence of chronic perivascular inflammation adjacent to the STA was considered to be of no clinical significance when this was the sole abnormality in the biopsy sections (19). In a minority of cases, we could not distinguish healed arteritis from senescent changes, (18) and these were classified as suggestive TABs. Negative TAB exhibited a normal histo-logical appearance and lacked any of the above histopatho-logical findings (18). RESULTS Two hundred thirteen consecutive TABs were identified. Nine TABs were excluded from analysis for the following reasons: 4 did not yield the STA, 3 were inadequate specimens, 1 was performed at an outside institution and El-Dairi et al: J Neuro-Ophthalmol 2015; 35: 246-253 247 Original Contribution Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. the original slides could not be retrieved for review. One biopsy was excluded because it was performed as part of a parotidectomy for a parotid tumor (the result of that biopsy was positive, but prebiopsy clinical and laboratory informa-tion was not available). A total of 204 TABs were analyzed. Forty-nine cases (24.0%) exhibited active or healed GCA (mean age, 74.8 ± 7.8 years), and 12 cases (5.9%) were suggestive of GCA (mean age 76.7 ± 6.5 years). One hun-dred and forty-three (70.0%) patients had a negative TAB (mean age 69.7 ± 11.0 years). Patients older than 65 years were more likely to have a positive TAB than those younger than 65 years (RR = 3.05, P = 0.0002). The youngest patient with a positive TAB was 54 years old (Table 1). Among the 143 patients with a negative TAB, the most common final diagnoses were primary headache (17.8%) and an autoimmune disease other than GCA or PMR (8.5%). The remaining alternative diagnoses are detailed in Table 2. One patient had a TAB consistent with Takayasu arteritis. Patients with diabetes mellitus and kidney disease (creatinine .2.0 mg/dL or estimated glomerular filtration rate ,30 mL/min) were less likely to have a positive TAB (RR = 0.331, P = 0.0007 and RR = 0.286, P = 0.0141, respectively). Thirty-three patients with negative TAB would have met ACR criteria for GCA. Five patients were given the diagnosis of TAB-negative GCA; of these, 2 had bilateral TABs. All 5 of these patients had ESR .60 mm/h, 2 patients had jaw claudication, 1 patient had bilateral cho-roidal ischemia, 1 patient had double vision, 1 patient had constitutional symptoms, and 3 patients had headaches. In all patients, the symptoms improved with the institution of oral corticosteroids. Twelve patients had a TAB that was considered suspicious for GCA. Three were not given the clinical diagnosis of GCA because another cause was identified (aortic hematoma, musculoskeletal headache, and age-related macular degeneration). Of the remaining 9 patients who were ultimately diagnosed with GCA, 2 of them had an optic neuropathy, 5 had headaches, 3 had jaw claudication, 1 had malaise, 1 had fever, and 4 had an elevated ESR. Of the 49 patients with positive TAB, the 3 most common findings on presentation were headache (38/47), vision change (16/46), and elevated ESR (33/46). Of the 9 (18.4%) patients who did not complain of headaches, 2 had scalp tenderness, 6 had vision loss, 1 had PMR without vision loss, two had constitutional symptoms, and all had elevated ESR. Of the patients who had vision loss, 9 (56.2%) presented with vision of less than 20/100. Only 1 patient presented with bilateral visual loss. The clinical sign that had the highest likelihood for positive TAB was jaw claudication (RR = 3.26; P = 0.0014). Isolated findings of headache, scalp tenderness, fever, weight loss, visual loss, and ischemia were not associated with a pos-itive TAB (Table 1). The majority (74.5%) of TABs were performed on females; however, there was no statistical difference in TAB outcome between men and women. Out of 52 African American patients who underwent TAB, 3 had a positive TAB and 2 had a suggestive TAB (RR for whites vs African Americans was 4.61; P = 0.0013; OR = 6.59). No Hispanic or Asian patients underwent a TAB during the study period. One patient from the Arabian Peninsula had a negative TAB. Race was not recorded in 4 patients with a negative TAB. The laboratory marker with the strongest association with positive TAB was an elevated platelet count greater than 400,000/mL (RR = 3.3; P = 0.0072) (Table 2). Ele-vated CRP had a RR of 1.8 (P = 0.037). ESR (.50 mm/h) or an elevated ESR after adjustment according to either the Hayreh or Miller formulas was not associated with a positive TAB (P . 0.18). When both ESR and CRP were elevated, the P value was 0.067. It should be noted that only 37.8% (77/204) subjects had a CRP before the TAB. When both ESR and platelet counts were elevated, RR was 2.01 (P = 0.017). Having any isolated laboratory value elevated, ESR, CRP, or platelet count was not associated with a positive TAB; however, when 2 or more inflammatory markers were elevated, the RR was 3.4 (P , 0.0001) (23/25 patients with elevated platelet count also had a high ESR, and 63/76 patients with a high CRP also had high ESR). An increase in ESR, CRP, and platelet count was present in 11 of 77 patients (14.7%) and was not associated with positive TAB. Two patients with positive TAB had normal ESR, CRP, and platelet counts. The majority of TABs were performed by the ophthal-mology service (136/204 [68%]) followed by otolaryngology (57/204 [28%]). Neurosurgery, vascular surgery, and general surgery were the other services that performed a TAB. The length of the STA did not vary greatly among the different subspecialties. The average length was 20.8 mm. Seven sequential and 5 simultaneous TABs were per-formed. In 2 patients (16.6%), there was a discordant pathologic diagnosis. Upon re-review of the original slides, the first biopsy in one of the 2 cases (performed at an outside institution) was believed to be positive, making the discordance rate 8.3%. Thirty-two patients with a positive TAB and 10 patients with suspicious TAB were on corticosteroid therapy before the TAB. Ten patients with a positive TAB had been on the steroids for more than 3 weeks, and 8 of them had been on the steroids for more than 2 months. Two patients with positive TAB had been on steroids for more than 1 year (Table 1). A longer segment biopsy was not associated with a higher rate of positive TAB (mean biopsy length 21.6 ± 4.1 for a negative TAB vs 21.6 ± 6.8, P = 0.49 for a positive TAB, P = 0.49). Both score models had a very high association with a positive or suspicious TAB (P , 0.001). For the 248 El-Dairi et al: J Neuro-Ophthalmol 2015; 35: 246-253 Original Contribution Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. TABLE 1. Temporal artery biopsy results with respect to demographics, symptoms, laboratory findings, clinical suspicion, and steroid treatment before biopsy Positive TAB Suggestive TAB Negative TAB (N = 49) (N = 12) (N = 143) P Relative Risk Odds Ratio Average age (range), yr 75 (54-89) 77 (62-86) 70 (41-90) 0.0002 Age .65 yrs 43/147 11/147 93/147 0.0002 3.05 4.28 Female sex (n/N) 37/145 9/145 99/145 0.12 White 45/146 10/146 91/146 0.0001 4.61 6.59 Headache 38/137 8/137 91/137 0.6 Evidence of anterior extracranial circulation ischemia/ischemic vision loss* 16/54 5/54 33/54 0.15 Jaw claudication 15/35 2/35 18/35 0.0014 3.26 3.45 PMR 3/15 1/15 11/15 0.55 Abnormal artery/scalp tenderness 22/69 4/69 22/69 0.074 Constitutional symptoms 2/20 2/20 16/20 ESR .50 mm/h 33/133 8/133 92/133 0.18 Elevated ESR per Miller formula 33/137 8/137 96/137 0.66 Elevated ESR per Hayreh formula 35/144 8/144 101/144 0.68 CRP .0.5 mg/dL 28/30 (93.3%) 7/7 (100.0%) 27/39 (69.2%) 0.037 1.8 2.6 Thrombocytosis .400,000/mL 10/25 3/25 12/25 0.0072 3.3 3.2 Any abnormal laboratory result (ESR .50 mm/h, CRP .0.5, mg/dL Platelets .400,000/mL) 38/148 9/148 101/148 0.32 Two or more abnormal test results 23/57 7/57 27/57 ,0.0001 3.4 3.6 Prior corticosteroid treatment in days (range) 48.7 (2 d to .3 yr) 12.1 (0-30 d) 17.7 (1 d to .1 yr) 0.07 *Seven anterior ischemic optic neuropathy, 4 transient vision loss, 4 retinal artery occlusion, 2 posterior ischemic optic neuropathy, 2 diplopia, 2 complained of decreased vision loss but no documented ophthalmic examination found. Eleven patients had no evidence of vision loss on follow-up examination. PMR, polymyalgia rheumatica; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. El-Dairi et al: J Neuro-Ophthalmol 2015; 35: 246-253 249 Original Contribution Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. nonweighted score, ROC was 0.8. Patients with a score of 1 (only 1 criterion suggestive of GCA) had 0% rate of a positive TAB (70 patients), those with a score of 2 had a 32.9% chance of a positive TAB (26/79), those with a score of 3 or higher had a 55.6% chance of a positive TAB (30/54) (score 3 = 19/39 [49%], score 4 = 6/9 [67%], score 5 = 5/7 [71.4%]), and with a score of 5 had biopsy negative GCA. None of our patients had more than 5 of these criteria. For the weighted score, the formula was 3.05 (if age .65 years) + 4.61 (if race = white) + 3.26 (if jaw claudication present) + 1.8 (if CRP higher than 0.5 mg/dL) + 3.3 (if platelets .400,000/L) + 3.4 (if .2 laboratory results abnormal). ROC for the weighted score was 0.77. A cut-point score of 8.5 had a positive predictive value of 0.82 and a negative predictive value of 0.53 for a positive TAB. DISCUSSION In our series, the yield of a positive or healed TAB was 24%, consistent with the previously published data ranging from 13.7% to 38.4% (5,6,8,20-24). Based on a comprehensive analysis of the demographic, clinical, and laboratory data of all the patients in this study, we developed an algorithm to quantitate the risk of GCA and increase the likelihood of positive TAB (Fig. 1). Given the potentially devastating visual and systemic complications associated with GCA and the relatively few surgical complications associated with a TAB, the low yield of a positive TAB seems justified in patients suspected of having GCA. However, the relatively low yield of obtaining a positive TAB indicates a deficiency in the ability of the clinician to reliably ascertain whether a patient has GCA based on clinical and laboratory findings. At this time, alternative diagnostic tools, such as Doppler ultrasonography and magnetic resonance imaging, cannot reliably replace a TAB (25). Although some have supported use of ACR criteria to diagnose GCA, (10,12), the rate of a negative TAB in patients meeting the ACR criteria has ranged from 15% to 39% (12,16,26). In our study, 21% of TAB-negative patients met at least 3 of the ACR criteria. In one series, while all GCA patients with a positive TAB met at least 3 ACR criteria, there were 68.5% of the negative TAB pa-tients who also met at least 3 of the ACR criteria (27). Conversely, Murchison et al (12) reported that 25.7% of their patients with a positive TAB would not have met the TABLE 2. Final diagnoses when temporal artery biopsy was normal Diagnosis Number of Patients Percentage List of Final Cause Primary headache syndrome 26 17.8 Symptoms could have been explained by patient's chronic condition 15 10.3 Worsening glaucoma, age-related macular degeneration, enlarging cavernous sinus aneurysm, known rheumatologic disease, known chronic infection, polio neuropathy, cancer Autoimmune disease other than GCA 12 8.2 Unidentified connective tissue disease, granulomatosis with polyangitis, Takayasu arteritis, Crohn disease, rheumatoid arthritis, systemic lupus erythematosus, optic neuritis, vitreoretinitis, Hashimoto thyroiditis, central centrifugal cicatricial alopecia Infection 11 7.5 Syphilis, meningitis, cervical facet osteoarthritis, hepatitis C, facial cellulitis, mycobacterium avium acellularis, ethmoid sinusitis, severe skin back infection, urinary tract infection Polymyalgia rheumatica 9 6.2 Symptoms resolved with no sequelae 8 5.5 Nonarteritic anterior ischemic optic neuropathy 6 4.1 Fibromyalgia 6 4.1 Cardiovascular disease 6 4.1 Carotid artery disease, progressive angina, hypertension, hypotension Symptoms explained after opththalmic examination 5 3.4 Vitreoretinitis, elevated intraocular pressure, corneal abrasion, blepharitis, skin nodule Iatrogenic 4 2.7 Amiodarone optic neuropathy, metformin myopathy, statin myopathy, cocaine vasculopathy Biopsy-negative giant cell arteritis 5 3.4 Total number of negative biopsies 143 GCA, giant cell arteritis. 250 El-Dairi et al: J Neuro-Ophthalmol 2015; 35: 246-253 Original Contribution Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. ACR criteria. All of our patients who had an ultimate diag-nosis of GCA met at least 3 of the ACR criteria. A TAB is considered the gold standard for confirming the diagnosing of GCA. A TAB is 100% specific for GCA but is not 100% sensitive (20,28). Niederkohr and Levin (28) estimated the sensitivity of a single TAB to be 87.1%. We found the sensitivity of a positive TAB was 91.4%, similar to the rate reported in the literature (29). In our study, the most common mimickers of GCA were primary headache syndrome, PMR, and chronic disease (diabetes mellitus and renal failure). Rheumatologic diseases (rheumatoid arthritis, systemic lupus erythematosus), lym-phoma, and vasculopathy also have been reported to mimic GCA (21). Similar to the results reported by Matthews et al (30), we found that patients with diabetes and kidney dis-ease were less likely to have a positive TAB. This does not imply that patients with diabetes or kidney disease are pro-tected from GCA, but clinicians should keep in mind that diabetes and kidney disease have vascular complications that may mimic GCA. Among our patients with a positive TAB, the most common presenting symptoms were headaches and vision loss. A new onset severe headache has been reported in approximately 2/3 of patients with GCA (15). Vision loss, one of the most feared complications of GCA, has been reported in 14%-70% of cases (3,31). Among our patients, 42.3% complained of vision changes and of those, 50% had permanent vision loss in 1 or both eyes due to retinal or FIG. 1. Algorithm to determine prebiopsy risk for giant cell arteritis. TAB, temporal artery biopsy; GCA, giant cell arteritis; AION, anterior ischemic optic neuropathy; PION, posterior ischemic optic neuropathy; CRAO, central retinal artery occlusion; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. El-Dairi et al: J Neuro-Ophthalmol 2015; 35: 246-253 251 Original Contribution Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. optic nerve ischemia. In our case series, the rate of perma-nent vision loss was 21.2% (Table 1). Among our patients, the most common abnormal laboratory measure was an elevated platelet count, followed by a high CRP. Elevation of these 2 inflammatory markers was highly predictive of a positive TAB, similar to pre-viously reported laboratory findings in GCA (22,23). Although an increase in any 2 laboratory markers was asso-ciated with a higher risk for a positive TAB, an increase in all 3 was not associated with a positive TAB. This is con-trary to previously published studies (22,23), and we sus-pect the reason for this finding is that only about one-third of our patients had all three markers measured before TAB. Also, in concordance with previous studies (15,24), jaw claudication was associated with the greatest likelihood of GCA while none of the other symptoms (e.g., headache, vision loss, abnormal STA, PMR) were predictive of GCA as isolated markers. In most cases, a unilateral TAB is often sufficient in suspected cases of GCA (32,33), but in 3%-5% of cases, there can be significant differences in the pathologic grade of disease from one side to the other in cases of bilateral TAB (30,31). The majority of our patients had a unilateral TAB, but of those patients who had a bilateral biopsy, the discordance rate was 8.3%. In an analysis of 11 pooled studies, Niederkohr and Levin (34) found the mean discor-dance rate for bilateral TAB to be 5.5%. Our discordance rate is higher than previously published studies, but our sample size of bilateral TAB was small. Based on our study and the low discordant rate published in the literature, we believe that a unilateral TAB is sufficient to exclude the diagnosis of GCA in patients for which there is a low clin-ical suspicion (33). Even with a high concordance in path-ologic diagnosis, a statistically significant difference can also be observed in the objective histopathologic severity scale between the 2 sides (35). The single patient in our study with a discordant result on bilateral TABs was likely due to the inadequate sampling on the initial TAB (9-mm seg-ment), although we cannot exclude the possibility of mis-interpreting the first specimen (the histopathologic slides were not available for our review). Although corticosteroid use decreases the inflammatory change in the vessel wall, it does not have an effect on scarring of the vascular media and surrounding the inner elastic lamina, thereby permitting a pathologic diagnosis (36,37). Even in patients who developed GCA with a his-tory of PMR and chronic low-dose corticosteroid use, TAB remained positive in 88% of cases in one study (26). Two of our patients who had been on chronic steroid therapy for more than 1 year had a positive TAB. We combined the results of our study with a review of the current literature to modify the algorithm published by Shmerling (38) for evaluating and treating suspected GCA (Fig. 1). The first step in the algorithm is to assess how many clinical and laboratory findings are consistent with GCA, which will determine the degree of clinical suspicion. If a patient meets less than 2 clinical or labo-ratory criteria, the likelihood of GCA is very low. If a patient meets 2 criteria, the likelihood of GCA is mod-erate (33%), and if a patient achieves 3 criteria, the likeli-hood is high (56%). We recognize the limitations of our studies. Being a retrospective study, medical records reviewed may have had incomplete documentation of symptoms, signs, and laboratory results. A number of patients were not tested for CRP and platelet count, and the clinical examination of the STA was not always documented. Intravenous fluorescein angiography was performed on only 7 of the patients in our study. We were not able to assess the prevalence of choroidal ischemia and the sensitivity of this test in predicting a positive TAB. Also, some patients did not undergo a follow-up ophthalmologic examination at our medical center and, as a result, we were unable to assess the risk of vision loss after low-dose or high-dose corticosteroid treatment. Given the relatively low prevalence of GCA, a multicentered prospective study with various ethnic representations would be necessary for controlling these limitations. REFERENCES 1. Chew SS, Kerr NM, Danesh-Meyer HV. Giant cell arteritis. J Clin Neurosci. 2009;16:1263-1268. 2. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, Liorca J. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454-1461. 3. Caselli RJ, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology. 1988;38:352-359. 4. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Hajeer AH, Branas F, Dababneh A, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79:283-292. 5. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311-317. 6. ICHD-II. Available at: http://ihs-classification.org/en/. Accessed December 14, 2014. 7. Brass SD, Durand ML, Stone JH, Chen JW, Stone JR. Case records of the Massachusetts General Hospital. Case 36- 2008. A 59-year-old man with chronic daily headache. N Engl J Med. 2008;359:2267-2278. 8. Stone JH, Papaliodis GN, Dunbar MR, Stone JR. Case records of the Massachusetts General Hospital. Case 4-2010. A 53- year-old man with arthralgias, oral ulcers, vision loss, and vocal-cord paralysis. N Engl J Med. 2010;362:537-546. 9. Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med. 1998;129:345-352. 10. Davies C, Frost B, Eshan O, McLain AD, Shandall A. Temporal artery biopsy. who needs one? Postgrad Med J. 2006;82:476-478. 11. Drehmer TJ, Khanna D, Markert RJ, Hawkins RA. Diagnostic and management trends of giant cell arteritis: a physician survey. J Rheumatol. 2005;32:1283-1289. 12. Murchison AP, Gilbert ME, Bilyk JR, Eagle RC Jr, Pueyo V, Sergott RC, Savino PJ. Validity of the American College of Rheumatology criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol. 2012;154:722-729. 252 El-Dairi et al: J Neuro-Ophthalmol 2015; 35: 246-253 Original Contribution Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. 13. Danesh-Meyer HV. Temporal artery biopsy: skip it at your patient's peril. Am J Ophthalmol. 2012;154:617-619. 14. Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed). 1983;286:266. 15. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997;123:285-296. 16. Taylor-Gjevre R, Vo M, Shukla D, Resch L. Temporal artery biopsy for giant cell arteritis. J Rheumatol. 2005;32:1279- 1282. 17. McDonnell PJ, Moore GW, Miller NR, Hutchins GM, Green WR. Temporal arteritis. A clinicopathologic study. Ophthalmology. 1986;93:518-530. 18. Lie JT, Brown AL Jr, Carter ET. Spectrum of aging changes in temporal arteries. Its significance, in interpretation of biopsy of temporal artery. Arch Pathol. 1970;90:278-285. 19. Corcoran GM, Prayson RA, Herzog KM. The significance of perivascular inflammation in the absence of arteritis in temporal artery biopsy specimens. Am J Clin Pathol. 2001;115:342-347. 20. Bhatti MT, Tabandeh H. Giant cell arteritis: diagnosis and management. Curr Opin Ophthalmol. 2001;12:393-399. 21. Roth AM, Mislow L, Keltner JL. The ultimate diagnoses of patients undergoing temporal artery biopsies. Arch Opthalmol. 1984;102:901-903. 22. Parikh M, Miller NR, Lee AG, Savino PJ, Vacarezza MN, Cornblath W, Eggenberger E, Antonio-Santos A, Golnik K, Kardon R, Wall M. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006:113:1842-1845. 23. Walvick MD, Walvick MP. Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy. Ophthalmology. 2011;118:1201-1204. 24. Salvarani C, Pipitone N, Versari A, Hunder GG. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol. 2012;8:509-521. 25. Kawasaki A, Purvin V. Giant cell arteritis: an updated review. Acta Ophthalmol. 2009;87:13-32. 26. Narvaez J, Bernad B, Roig-Vilaseca D, Garcia-Gomez C, Gomez- Vaquero C, Juanola X, Rodriquez-Moreno J, Nolla JM, Valverde J. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum. 2007;37:13-19. 27. Mari B, Monteagudo M, Bustamante E, Perez J, Casanovas A, Jordana R, Tolosa C, Oristrell J. Analysis of temporal artery biopsies in an 18-year period at a community hospital. Eur J Intern Med. 2009:20:533-536. 28. Niederkohr RD, Levin LA. A Bayesian analysis of the true sensitivity of a temporal artery biopsy. Invest Ophthalmol Vis Sci. 2007;48:675-680. 29. Hedges TR, Gieger GL, Albert DM. The clinical value of negative temporal artery biopsy specimens. Arch Ophthalmol. 1983;101:1251-1254. 30. Matthews JL, Gilbert DN, Farris BK, Siatkowski RM. Prevalence of diabetes mellitus in biopsy-positive giant cell arteritis. J Neuroophthalmol. 2012;32:202-206. 31. Huston KA, Hunder GG, Lie JT, Kennedy RH, Elveback LR. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. 1978;88:162-167. 32. Boyev LR, Miller NR, Green WR. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol. 1999;128:211-215. 33. Hall JK, Volpe NJ, Galetta SL, Liu GT, Syed NA, Balcer LJ. The role of unilateral temporal artery biopsy. Ophthalmology. 2003;110:543-548. 34. Niederkohr RD, Levin LA. Management of the patient with suspected temporal arteritis a decision-analytic approach. Ophthalmology. 2005;112:744-756. 35. Diaz VA, DeBroff BM, Sinard J. Comparison of histopathologic features, clinical symptoms, and erythrocyte sedimentation rates in biopsy-positive temporal arteritis. Ophthalmology. 2005;112:1293-1298. 36. Font RL, Prabhakaran VC. Histological parameters helpful in recognizing steroid-treated temporal arteritis: an analysis of 35 cases. Br J Ophthalmol. 2007;91:204-209. 37. Zhou L, Luneau K, Weyand CM, Biousse V, Newman NJ, Grossniklaus HE. Clinicopathologic correlations in giant cell arteritis: a retrospective study of 107 cases. Ophthalmology. 2009;116:1574-1580. 38. Shmerling RH. An 81-year-old woman with temporal arteritis. JAMA. 2006;295:2525-2534. El-Dairi et al: J Neuro-Ophthalmol 2015; 35: 246-253 253 Original Contribution Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. |
